TherapeuticsMD Receives Buy Rating from Noble Financial (TXMD)
TherapeuticsMD (NASDAQ:TXMD)‘s stock had its “buy” rating reiterated by Noble Financial in a research note issued on Tuesday, StockRatingsNetwork.com reports.
In other TherapeuticsMD news, CEO Robert G. Finizio sold 50,000 shares of the stock on the open market in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $5.70, for a total transaction of $285,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
TherapeuticsMD (NASDAQ:TXMD) traded up 5.30% on Tuesday, hitting $5.96. The stock had a trading volume of 706,701 shares. TherapeuticsMD has a one year low of $1.65 and a one year high of $6.10. The stock’s 50-day moving average is $5.16 and its 200-day moving average is $3.70. The company’s market cap is $864.0 million.
TXMD has been the subject of a number of other recent research reports. Analysts at Cowen and Company initiated coverage on shares of TherapeuticsMD in a research note to investors on Wednesday, January 8th. They set an “outperform” rating on the stock. Analysts at Stifel Nicolaus initiated coverage on shares of TherapeuticsMD in a research note to investors on Friday, November 1st. They set a “buy” rating and a $8.00 price target on the stock.
TherapeuticsMD, Inc promotes, distributes and sells certain products developed and sold by Spectrum Health Network, Inc (NASDAQ:TXMD) relative to its digital media network.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.